European pharma strategy report approved with huge majority

A report constituting the EU Parliament's contribution to the Commission's upcoming pharmaceutical legislation was adopted on Wednesday.

Photo: AJ Vaccines

BRUSSELS – The reduction to the lifetime of pharmaceutical patents has come one step closer to having a permanent place in European law.

On Wednesday, the EU Parliament approved the report that forms the basis of the strategy text with a significant majority, with 527 votes for the strategy out of a possible 689.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs